AJMC ®: Paroxysmal nocturnal hemoglobinuria (PNH) is 1 of several complement-driven diseases. Can you describe its clinical presentation? DE CASTRO: PNH presents heterogeneously. One of the 3 ...
The US Food and Drug Administration has approved danicopan (Voydeya, AstraZeneca) as an add-on therapy to treat extravascular hemolysis in adults receiving ravulizumab or eculizumab for paroxysmal ...
The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...
Voydeya is a first-in-class, oral, factor D inhibitor. The Food and Drug Administration (FDA) has approved Voydeya ™ (danicopan) as add-on therapy to ravulizumab or eculizumab for the treatment of ...
SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, ...
In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...
ASH 2025 highlighted many investigational agents for paroxysmal nocturnal hemoglobinuria (PNH) that may not reach clinical practice soon, notes Dr Jamile M. Shammo, though bispecific antibodies show ...
Treating Paroxysmal Nocturnal Hemoglobinuria: PNH is a rare, acquired hematologic disease characterized by complement-mediated hemolysis, fatigue, susceptibility to thrombosis, and bone marrow ...
Credit: Novartis. The approval was based on data from the phase 3 APPLY-PNH trial. Health care providers who prescribe Fabhalta must enroll in the Fabhalta REMS. The Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results